Novel relaxin-3 mimetics for controlling feeding and motivated behaviour

Eating disorders and addictions, in particular obesity and excessive food consumption, are a major health concern in Australia and worldwide; and there is an urgent need to better and fully define the neurochemicals and neural circuits controlling motivated appetitive and consummatory behaviours.

Relaxin-3 (R3) is a highly conserved neuropeptide transmitter that can regulate a number of important physiological processes including arousal-, stress- and reward-related circuits and resultant behaviours, including feeding.

Central administration of R3 or agonist analogues increases feeding, while antagonizing R3 signalling inhibits consumption of highly-palatable food and other appetitive drives.

These findings suggest that the R3 receptor, RXFP3, is a potential target for pharmacological control of eating and addictive disorders.

The characterization of the physiological functions of R3/RXFP3 signalling has, however, been hampered by a lack of selective and readily available ligands for RXFP3.

Exogenous native R3 has poor selectivity for RXFP3 and its complex two-chain peptide structure renders it difficult and expensive to produce chemically. In a major breakthrough, our team together with our collaborator Dr Johan Rosengren overcome these limitations by developing potent minimized peptide agonists and antagonists for RXFP3, the first single-chain relaxin peptide analogues with nanomolar affinity.

The objectives of this proposal are to use innovative medicinal chemistry approaches to further develop/modify these linear peptides to optimize BBB penetration and in vivo stability; and to use these peptides to study the role of the R3/RXFP3 system in modulating neuronal signalling and behaviour in order to validate it as a drug target.

These novel peptides are patented and they represent new leads for future development and preclinical testing.

Support us

Brain health affects all Australians.
You can support our research by making a donation or a bequest.


Latest breakthroughs, news, events & more.